
Lupin Ltd (LUPIN) - Financial and Strategic SWOT Analysis Review
Description
Lupin Ltd (LUPIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
rLupin Ltd (Lupin) is a pharmaceutical company primarily engaged in the development and distribution of a diverse range of healthcare products. The company's portfolio includes products with a focus on generics, branded generics, complex generics, APIs, biosimilars, and specialty medicines. Lupin's products cater to various therapeutic areas such as anti-tuberculosis, diabetes, cardiovascular, respiratory, women's health, and the central nervous system. The company offers generic medicines related to anti-TB, diabetes, cardiovascular, respiratory, and ophthalmic. Its biosimilar products include Filgrastim, Peg-Filgrastim, and Etanercept, and specialty products are focused on women's health and rare neurological disorders. Lupin also develops value-added generic pharmaceuticals based on its platform technologies. The company has its manufacturing units in India, the US, Mexico, and Brazil. Lupin is headquartered in Mumbai, Maharashtra, India.
Lupin Ltd Key Recent Developments
Aug 05,2025: Lupin Reports Financial Performance for Quarter Ending June 30, 2025
Jul 17,2025: Lupin : Disclosure Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’)
Jul 17,2025: Lupin : Disclosure Pursuant to Regulation 30 of Securities and Exchange Board of India Regulations, 2015 (‘SEBI Listing Regulations’)
Jul 17,2025: Lupin Achieves GMP Certification From TGA Australia for Dabhasa API Facility
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note:Some sections may be missing if data is unavailable for the company
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
rLupin Ltd (Lupin) is a pharmaceutical company primarily engaged in the development and distribution of a diverse range of healthcare products. The company's portfolio includes products with a focus on generics, branded generics, complex generics, APIs, biosimilars, and specialty medicines. Lupin's products cater to various therapeutic areas such as anti-tuberculosis, diabetes, cardiovascular, respiratory, women's health, and the central nervous system. The company offers generic medicines related to anti-TB, diabetes, cardiovascular, respiratory, and ophthalmic. Its biosimilar products include Filgrastim, Peg-Filgrastim, and Etanercept, and specialty products are focused on women's health and rare neurological disorders. Lupin also develops value-added generic pharmaceuticals based on its platform technologies. The company has its manufacturing units in India, the US, Mexico, and Brazil. Lupin is headquartered in Mumbai, Maharashtra, India.
Lupin Ltd Key Recent Developments
Aug 05,2025: Lupin Reports Financial Performance for Quarter Ending June 30, 2025
Jul 17,2025: Lupin : Disclosure Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’)
Jul 17,2025: Lupin : Disclosure Pursuant to Regulation 30 of Securities and Exchange Board of India Regulations, 2015 (‘SEBI Listing Regulations’)
Jul 17,2025: Lupin Achieves GMP Certification From TGA Australia for Dabhasa API Facility
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note:Some sections may be missing if data is unavailable for the company
Table of Contents
73 Pages
- Section 1 - About the Company
- Lupin Ltd - Key Facts
- Lupin Ltd - Key Employees
- Lupin Ltd - Key Employee Biographies
- Lupin Ltd - Major Products and Services
- Lupin Ltd - History
- Lupin Ltd - Company Statement
- Lupin Ltd - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Section 2 – Company Analysis
- Company Overview
- Lupin Ltd - Business Description
- Business Segment: Others
- Overview
- Performance
- Business Segment: Pharmaceuticals
- Overview
- Performance
- Geographical Segment: India
- Performance
- Geographical Segment: Others
- Performance
- Geographical Segment: USA
- Performance
- R&D Overview
- Lupin Ltd - Corporate Strategy
- Lupin Ltd - SWOT Analysis
- SWOT Analysis - Overview
- Lupin Ltd - Strengths
- Lupin Ltd - Weaknesses
- Lupin Ltd - Opportunities
- Lupin Ltd - Threats
- Lupin Ltd - Key Competitors
- Section 3 – Company Financial Ratios
- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts
- Section 4 – Company’s Lifesciences, Power Financial Deals and Alliances
- Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
- Lupin Ltd, Recent Deals Summary
- Section 5 – Company’s Recent Developments
- Aug 05, 2025: Lupin Reports Financial Performance for Quarter Ending June 30, 2025
- Jul 17, 2025: Lupin : Disclosure Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’)
- Jul 17, 2025: Lupin : Disclosure Pursuant to Regulation 30 of Securities and Exchange Board of India Regulations, 2015 (‘SEBI Listing Regulations’)
- Jul 17, 2025: Lupin Achieves GMP Certification From TGA Australia for Dabhasa API Facility
- Jul 10, 2025: Lupin and Zentiva in licence and supply deal for Certolizumab Pegol
- Jun 05, 2025: Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation
- May 15, 2025: Lupin Appoints Punita Lal as Additional Director
- May 14, 2025: Lupin Announces Financial Performance for Quarter and Fiscal Year Ending March 31, 2025
- May 14, 2025: Lupin : Change in Directorate
- Apr 23, 2025: Lupin Diagnostics Achieves NABL Accreditation for All Greenfield Labs
- Section 6 – Appendix
- Methodology
- Ratio Definitions
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- Lupin Ltd, Key Facts
- Lupin Ltd, Key Employees
- Lupin Ltd, Key Employee Biographies
- Lupin Ltd, Major Products and Services
- Lupin Ltd, History
- Lupin Ltd, Subsidiaries
- Lupin Ltd, Key Competitors
- Lupin Ltd, Ratios based on current share price
- Lupin Ltd, Annual Ratios
- Lupin Ltd, Annual Ratios (Cont...1)
- Lupin Ltd, Annual Ratios (Cont...2)
- Lupin Ltd, Interim Ratios
- Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
- Lupin Ltd, Recent Deals Summary
- Currency Codes
- Capital Market Ratios
- Equity Ratios
- Profitability Ratios
- Cost Ratios
- Liquidity Ratios
- Leverage Ratios
- Efficiency Ratios
- List of Figures
- Lupin Ltd, Performance Chart (2021 - 2025)
- Lupin Ltd, Ratio Charts
- Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- Lupin Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2019 to YTD 2025
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.